RGL4

Summary

RGL4 (ral guanine nucleotide dissociation stimulator like 4, HGNC:31911) is a protein-coding gene on chromosome 22q11.23, encoding Ral-GDS-related protein (Q8IZJ4).

This oncogene encodes a protein similar to guanine nucleotide exchange factor Ral guanine dissociation stimulator. Increased expression of this gene leads to translocation of the encoded protein to the cell membrane. The encoded protein can activate several pathways, including the Ras-Raf-MEK-ERK cascade.

Source: NCBI Gene 266747 — RefSeq curated summary.

At a glance

• Gene–disease (curated): retinitis pigmentosa (Supportive, GenCC) — +1 more curated relationship
• GWAS associations: 3
• Clinical variants (ClinVar): 421 total — 1 pathogenic, 1 likely-pathogenic
• Phenotypes (HPO): 1
• MANE Select transcript: NM_153615

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:31911
Approved symbol	RGL4
Name	ral guanine nucleotide dissociation stimulator like 4
Location	22q11.23
Locus type	gene with protein product
Status	Approved
Aliases	Rgr
Ensembl gene	ENSG00000159496
Ensembl biotype	protein_coding
OMIM	612214
Entrez	266747

Gene structure

Transcript identifiers

Ensembl transcripts: 10 — 6 protein_coding, 2 retained_intron, 1 nonsense_mediated_decay, 1 protein_coding_CDS_not_defined

ENST00000290691, ENST00000401461, ENST00000423392, ENST00000441897, ENST00000452208, ENST00000460003, ENST00000460167, ENST00000467354, ENST00000612432, ENST00000615003

RefSeq mRNA: 3 — MANE Select: NM_153615 NM_001329424, NM_001329425, NM_153615

CCDS: CCDS13811

Canonical transcript exons

ENST00000290691 — 11 exons

Exon	Start	End
ENSE00002305444	23691013	23692209
ENSE00003461694	23697838	23697861
ENSE00003491804	23692335	23692528
ENSE00003555602	23697171	23697245
ENSE00003580498	23694950	23695019
ENSE00003601906	23693759	23693974
ENSE00003609268	23696614	23696688
ENSE00003631118	23694347	23694450
ENSE00003667662	23698212	23698333
ENSE00003670665	23692669	23692991
ENSE00003918580	23698844	23699168

Expression profiles

Bgee: expression breadth ubiquitous, 155 present calls, max score 95.35.

FANTOM5 (CAGE): breadth broad, TPM avg 5.2995 / max 1505.8311, expressed in 186 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
191317	5.2788	182
191316	0.0208	5

Top tissues by expression

244 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
bone marrow	UBERON:0002371	95.35	gold quality
bone marrow cell	CL:0002092	93.07	gold quality
blood	UBERON:0000178	92.42	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	86.79	gold quality
granulocyte	CL:0000094	86.03	gold quality
trabecular bone tissue	UBERON:0002483	84.33	gold quality
spleen	UBERON:0002106	84.13	gold quality
vermiform appendix	UBERON:0001154	80.33	gold quality
leukocyte	CL:0000738	78.54	gold quality
monocyte	CL:0000576	77.85	gold quality
lymph node	UBERON:0000029	77.72	gold quality
right lung	UBERON:0002167	74.86	gold quality
left testis	UBERON:0004533	72.32	gold quality
right testis	UBERON:0004534	71.83	gold quality
caecum	UBERON:0001153	71.75	gold quality
upper lobe of left lung	UBERON:0008952	70.81	gold quality
sperm	CL:0000019	70.06	gold quality
testis	UBERON:0000473	69.61	gold quality
upper lobe of lung	UBERON:0008948	68.52	gold quality
gall bladder	UBERON:0002110	68.03	gold quality
tonsil	UBERON:0002372	67.08	gold quality
rectum	UBERON:0001052	64.19	gold quality
colonic epithelium	UBERON:0000397	64.10	silver quality
amniotic fluid	UBERON:0000173	63.50	silver quality
small intestine Peyer’s patch	UBERON:0003454	61.96	gold quality
right lobe of liver	UBERON:0001114	61.88	gold quality
lung	UBERON:0002048	61.51	gold quality
small intestine	UBERON:0002108	61.50	gold quality
omental fat pad	UBERON:0010414	61.43	gold quality
peritoneum	UBERON:0002358	61.38	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-MTAB-9801	yes	6.47
E-ANND-3	yes	5.67
E-HCAD-30	no	46.27

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

18 targeting RGL4, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-4789-5P	99.98	70.76	2721
HSA-MIR-4803	99.98	71.99	3117
HSA-MIR-548AT-5P	99.96	70.83	2666
HSA-MIR-10394-5P	99.65	66.83	1852
HSA-MIR-1205	99.65	66.76	1826
HSA-MIR-6081	99.48	66.07	1446
HSA-MIR-4685-5P	99.25	65.99	1563
HSA-MIR-6837-5P	99.25	65.47	1632
HSA-MIR-548AS-3P	99.12	69.12	2294
HSA-MIR-4744	99.01	69.91	1581
HSA-MIR-3190-5P	98.87	64.89	1345
HSA-MIR-6776-5P	98.54	67.43	1304
HSA-MIR-4252	98.45	66.37	987
HSA-MIR-5585-3P	98.25	67.41	941
HSA-MIR-6791-3P	97.45	64.31	1123
HSA-MIR-6829-3P	97.45	64.31	1137
HSA-MIR-4485-5P	95.91	59.69	198

Literature-anchored findings (GeneRIF, showing 2)

• Human rgr: transforming activity and alteration in T-cell malignancies [rgr: ralGDS-related] (PMID:12140761)
• Low expression of RGL4 is associated with a poor prognosis and immune infiltration in lung adenocarcinoma patients. (PMID:32259700)

Cross-species orthologs

0 orthologs

Paralogs (24): RASGRF1 (ENSG00000058335), RASGRP2 (ENSG00000068831), RAPGEF3 (ENSG00000079337), RAPGEF4 (ENSG00000091428), SOS2 (ENSG00000100485), RAPGEF1 (ENSG00000107263), RAPGEFL1 (ENSG00000108352), RAPGEF2 (ENSG00000109756), RASGRF2 (ENSG00000113319), SOS1 (ENSG00000115904), RALGPS2 (ENSG00000116191), RAPGEF5 (ENSG00000136237), RALGPS1 (ENSG00000136828), RASGEF1B (ENSG00000138670), RGL1 (ENSG00000143344), RASGEF1C (ENSG00000146090), RASGRP3 (ENSG00000152689), RAPGEF6 (ENSG00000158987), RALGDS (ENSG00000160271), RASGRP4 (ENSG00000171777), RASGRP1 (ENSG00000172575), RASGEF1A (ENSG00000198915), RGL3 (ENSG00000205517), RGL2 (ENSG00000237441)

Protein

Protein identifiers

Ral-GDS-related protein — Q8IZJ4 (reviewed: Q8IZJ4)

Alternative names: Ral guanine nucleotide dissociation stimulator-like 4

All UniProt accessions (7): Q8IZJ4, A0A087WWL2, A0A087X1Z6, B5MCW5, E7EPT8, E9PH21, H7C063

UniProt curated annotations — full annotation on UniProt →

Subcellular location. Cytoplasmic vesicle.

Isoforms (2)

UniProt ID	Names	Canonical?
Q8IZJ4-1	1	yes
Q8IZJ4-2	2

RefSeq proteins (3): NP_001316353, NP_001316354, NP_705843* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001895	RASGEF_cat_dom	Domain
IPR008937	Ras-like_GEF	Family
IPR023578	Ras_GEF_dom_sf	Homologous_superfamily
IPR036964	RASGEF_cat_dom_sf	Homologous_superfamily

Pfam: PF00617

UniProt features (14 total): sequence variant 8, compositionally biased region 2, chain 1, domain 1, region of interest 1, splice variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8IZJ4-F1	62.88	0.29

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 197 (showing top): GSE45365_CD8A_DC_VS_CD11B_DC_IFNAR_KO_MCMV_INFECTION_DN, GOBP_CELLULAR_RESPONSE_TO_LIGHT_STIMULUS, GOBP_PHOTOTRANSDUCTION, CAGCTG_AP4_Q5, MODULE_289, GOBP_SENSORY_PERCEPTION_OF_LIGHT_STIMULUS, GOBP_RAS_PROTEIN_SIGNAL_TRANSDUCTION, GOBP_RESPONSE_TO_RADIATION, MODULE_123, GOBP_DETECTION_OF_LIGHT_STIMULUS, GOBP_RESPONSE_TO_ABIOTIC_STIMULUS, GOBP_DETECTION_OF_ABIOTIC_STIMULUS, MODULE_113, GOBP_DETECTION_OF_STIMULUS, GOBP_CELLULAR_RESPONSE_TO_RADIATION

GO Biological Process (2): Ras protein signal transduction (GO:0007265), small GTPase-mediated signal transduction (GO:0007264)

GO Molecular Function (1): guanyl-nucleotide exchange factor activity (GO:0005085)

GO Cellular Component (2): plasma membrane (GO:0005886), cytoplasmic vesicle (GO:0031410)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
small GTPase-mediated signal transduction	1
intracellular signaling cassette	1
GTP binding	1
GDP binding	1
GTPase regulator activity	1
membrane	1
cell periphery	1
cytoplasm	1
intracellular vesicle	1

Protein interactions and networks

STRING

400 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
RGL4	RALA	P11233	844
RGL4	DRICH1	Q6PGQ1	540
RGL4	HRAS	P01112	529
RGL4	LRRC75B	Q2VPJ9	507
RGL4	C22orf15	Q8WYQ4	479
RGL4	ZNF70	Q9UC06	447
RGL4	RGR	P47804	446
RGL4	SPRING1	Q9H741	415
RGL4	SOWAHC	Q53LP3	397
RGL4	RASSF9	O75901	396
RGL4	TM9SF3	Q9HD45	367
RGL4	F5GXT2	F5GXT2	358
RGL4	RASSF10	A6NK89	357
RGL4	GUCD1	Q96NT3	349
RGL4	F8WDG0	F8WDG0	337

IntAct

2 interactions, top by confidence:

A	B	Type	Score
RGL4	DCX	psi-mi:“MI:0914”(association)	0.350

BioGRID (14): OCIAD1 (Affinity Capture-MS), DCX (Affinity Capture-MS), OCIAD1 (Affinity Capture-MS), RGL4 (Two-hybrid), RGL4 (Affinity Capture-MS), HRAS (Reconstituted Complex), RALA (Reconstituted Complex), RALB (Reconstituted Complex), RAP1A (Reconstituted Complex), RGL4 (Synthetic Lethality), RGL4 (Negative Genetic), DCX (Affinity Capture-MS), OCIAD1 (Affinity Capture-MS), RGL4 (Affinity Capture-RNA)

ESM2 similar proteins: A0A494C1R9, A2AKB4, A2APT9, A6NKD2, A8MT33, B0BN44, E9PGG2, F5GYI3, O19110, O88852, P0CV98, P0CV99, P0CW00, P0CW01, Q01534, Q03386, Q0P5N2, Q12967, Q14684, Q2M329, Q3U3N0, Q5F267, Q5I0E2, Q5R5G8, Q5R866, Q5SYB0, Q5VTJ3, Q60953, Q69ZB3, Q6ZUX3, Q7TQI8, Q80VJ8, Q80VR2, Q86VY4, Q8BSI6, Q8IZJ4, Q8N831, Q8VD63, Q95LS7, Q96FG2

Diamond homologs: A2CEA7, A7A0P0, B3LTF3, B5VMS9, C8ZCV7, F1M386, F1MSG6, F1PBJ0, G5EDB9, O14827, O77086, P04821, P0CF32, P0CF33, P0CF34, P27671, P28818, P43069, P70392, Q02342, Q13972, Q54FF3, Q552M5, Q86G47, Q8CHG7, Q8IS18, Q8IS20, Q8IZJ4, Q8TEU7, Q99JE4, Q9Y4G8, A6N9I4, P0C643, Q0VAM2, Q13905, Q1LZ97, Q28EC1, Q54TK8, Q55FD8, Q55GH9

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

421 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	1
Uncertain significance	258
Likely benign	122
Benign	9

Top pathogenic / likely-pathogenic (2)

Variant ID	HGVS	Classification
438065	NM_001012720.2(RGR):c.*74dup	Pathogenic
802599	NM_001012720.2(RGR):c.820del (p.Arg274fs)	Likely pathogenic

SpliceAI

3832 predictions. Top by Δscore:

Variant	Effect	Δscore
10:84232904:C:CC	acceptor_gain	1.0000
10:84234220:T:TA	donor_gain	1.0000
10:84234375:AGCC:A	acceptor_gain	1.0000
10:84234376:GCC:G	acceptor_gain	1.0000
10:84234377:CCC:C	acceptor_gain	1.0000
10:84234379:C:CC	acceptor_gain	1.0000
10:84234380:T:A	acceptor_loss	1.0000
10:84234387:G:GC	acceptor_gain	1.0000
10:84247639:A:G	acceptor_gain	1.0000
10:84254324:A:AG	acceptor_gain	1.0000
10:84254325:G:GG	acceptor_gain	1.0000
10:84254325:GA:G	acceptor_gain	1.0000
10:84254440:CCAGG:C	donor_loss	1.0000
10:84254443:GGTAA:G	donor_loss	1.0000
10:84254444:G:GA	donor_loss	1.0000
10:84254445:T:A	donor_loss	1.0000
10:84258013:A:G	donor_gain	1.0000
10:84258022:G:GG	donor_gain	1.0000
22:23692360:T:A	acceptor_gain	1.0000
22:23693973:GG:G	donor_gain	1.0000
22:23693974:GG:G	donor_gain	1.0000
22:23694941:T:TA	acceptor_gain	1.0000
22:23694945:CATA:C	acceptor_loss	1.0000
22:23694947:T:G	acceptor_gain	1.0000
22:23694947:TA:T	acceptor_loss	1.0000
22:23694948:A:AG	acceptor_gain	1.0000
22:23694948:A:C	acceptor_loss	1.0000
22:23694949:G:GG	acceptor_gain	1.0000
22:23694949:GC:G	acceptor_gain	1.0000
22:23694949:GCA:G	acceptor_gain	1.0000

AlphaMissense

3073 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
22:23697195:T:C	F396L	0.956
22:23697197:T:A	F396L	0.956
22:23697197:T:G	F396L	0.956
22:23693765:T:C	F235L	0.939
22:23693767:C:A	F235L	0.939
22:23693767:C:G	F235L	0.939
22:23697183:T:C	F392L	0.936
22:23697185:C:A	F392L	0.936
22:23697185:C:G	F392L	0.936
22:23692429:T:C	F92L	0.900
22:23692431:C:A	F92L	0.900
22:23692431:C:G	F92L	0.900
22:23693850:T:A	V263D	0.899
22:23693766:T:C	F235S	0.889
22:23697178:T:A	V390D	0.889
22:23697181:C:A	P391H	0.887
22:23698287:T:C	F446L	0.887
22:23698289:T:A	F446L	0.887
22:23698289:T:G	F446L	0.887
22:23692947:T:C	F218L	0.886
22:23692949:C:A	F218L	0.886
22:23692949:C:G	F218L	0.886
22:23698240:T:C	L430P	0.873
22:23693957:T:A	W299R	0.871
22:23693957:T:C	W299R	0.871
22:23694352:C:G	C306W	0.871
22:23697180:C:T	P391S	0.869
22:23694368:T:C	F312L	0.866
22:23694370:C:A	F312L	0.866
22:23694370:C:G	F312L	0.866

dbSNP variants (sampled 300 via entrez): RS1000397086 (22:23691627 T>C), RS1000608932 (22:23690629 G>C), RS1000739896 (22:23695445 C>T), RS1000760817 (22:23695102 T>A), RS1000791273 (22:23695615 G>A), RS1001004157 (22:23690610 A>G), RS1001431158 (22:23696959 T>C), RS1001741870 (22:23699446 T>C), RS1001995467 (22:23689165 T>G), RS1002045735 (22:23699265 A>C), RS1002408569 (22:23689428 C>T), RS1002426940 (22:23695957 G>T), RS1002687053 (22:23691690 G>T), RS1002750416 (22:23693075 G>A,C,T), RS1002804458 (22:23693410 C>T)

Disease associations

OMIM: gene MIM:612214 | disease phenotypes: MIM:268000, MIM:613769

GenCC curated gene-disease

Disease	Classification	Inheritance
retinitis pigmentosa	Supportive	Autosomal dominant
retinitis pigmentosa 44	Limited	Semidominant

Mondo (5): inherited retinal dystrophy (MONDO:0019118), retinitis pigmentosa (MONDO:0019200), retinitis pigmentosa 44 (MONDO:0013414), optic atrophy (MONDO:0003608), cone dystrophy (MONDO:0000455)

Orphanet (3): OBSOLETE: Inherited retinal disorder (Orphanet:71862), Retinitis pigmentosa (Orphanet:791), Progressive cone dystrophy (Orphanet:1871)

HPO phenotypes

1 total (1 of 1 shown, HPO-id order):

HPO	Term
HP:0000556	Retinal dystrophy

GWAS associations

3 associations (top):

Study	Trait	p-value
GCST003997_33	Myopia	6.000000e-19
GCST009962_12	High myopia	4.000000e-11
GCST010002_293	Refractive error	1.000000e-70

MeSH disease descriptors (4)

Descriptor	Name	Tree numbers
D000077765	Cone Dystrophy	C11.270.151; C11.768.216
D009896	Optic Atrophy	C10.292.700.225; C11.640.451
D058499	Retinal Dystrophies	C11.768.585.658
D012174	Retinitis Pigmentosa	C11.270.684; C11.768.585.658.500; C16.320.290.684

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB clinical annotations

1 annotations.

Variant	Type	Level	Drugs	Phenotypes
rs184199168	Metabolism/PK	3	o-desmethyltramadol;tramadol

PharmGKB variants

1 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs184199168	RGL4	3	1.50	1	o-desmethyltramadol;tramadol

CTD chemical–gene interactions

16 total (human), top 16 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Nickel	increases expression	2
GSK-J4	decreases expression	1
triphenyl phosphate	affects expression	1
sodium arsenite	increases expression	1
di-n-butylphosphoric acid	affects expression	1
CGP 52608	affects binding, increases reaction	1
jinfukang	increases expression	1
Norethindrone Acetate	affects cotreatment, increases expression	1
Benzo(a)pyrene	increases mutagenesis	1
Cisplatin	increases expression	1
Diuron	decreases expression	1
Estradiol	affects cotreatment, increases expression	1
Paraquat	decreases expression	1
Tretinoin	increases expression	1
Valproic Acid	increases methylation	1
Copper Sulfate	decreases expression	1

Clinical trials (associated diseases)

259 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00717080	PHASE4	COMPLETED	The Role of Capsular Tension Ring (CTR) in Anterior Capsular Contraction
NCT00000114	PHASE3	COMPLETED	Randomized Trial of Vitamin A and Vitamin E Supplementation for Retinitis Pigmentosa
NCT00000116	PHASE3	COMPLETED	Randomized Trial of DHA for Retinitis Pigmentosa Patients Receiving Vitamin A
NCT00346333	PHASE3	COMPLETED	Clinical Trial of Lutein for Patients With Retinitis Pigmentosa Receiving Vitamin A
NCT01786395	PHASE3	TERMINATED	Phase III Efficacy and Safety Clinical Study of UF-021 for Treatment of Retinitis Pigmentosa
NCT04224207	PHASE3	COMPLETED	Management of Retinitis Pigmentosa by Mesenchymal Stem Cells by Wharton’s Jelly Derived Mesenchymal Stem Cells
NCT04636853	PHASE3	COMPLETED	CB-PRP in Retinitis Pigmentosa and Dry Age-related Macular Degeneration
NCT05537220	PHASE3	ACTIVE_NOT_RECRUITING	Oral N-acetylcysteine for Retinitis Pigmentosa
NCT05800301	PHASE3	COMPLETED	Management of Retinitis Pigmentosa Via Combination of Wharton’s Jelly-derived Mesenchymal Stem Cells and Magnovision
NCT05926583	PHASE3	ACTIVE_NOT_RECRUITING	A Study of AAV5-hRKp.RPGR for the Treatment of Japanese Participants With X-linked Retinitis Pigmentosa
NCT06388200	PHASE3	ACTIVE_NOT_RECRUITING	A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa
NCT07082855	PHASE3	NOT_YET_RECRUITING	A Multicenter, Randomized, Double-Blind, Controlled Clinical Study of Minocycline for the Treatment of Retinitis Pigmentosa
NCT07290530	PHASE3	NOT_YET_RECRUITING	24-Month Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher Syndrome
NCT00100230	PHASE2	COMPLETED	DHA and X-Linked Retinitis Pigmentosa
NCT00447980	PHASE2	COMPLETED	A Study of Encapsulated Cell Technology (ECT) Implant for Participants With Early Stage Retinitis Pigmentosa
NCT00447993	PHASE2	COMPLETED	A Study of Encapsulated Cell Technology (ECT) Implant for Patients With Late Stage Retinitis Pigmentosa
NCT01233609	PHASE2	COMPLETED	Trial of Oral Valproic Acid for Retinitis Pigmentosa
NCT01399515	PHASE2	COMPLETED	Efficacy and Safety of Oral Valproic Acid for Retinitis Pigmentosa
NCT01530659	PHASE2	COMPLETED	Retinal Imaging in CNTF -Releasing Encapsulated Cell Implant Treated Patients for Early-stage Retinitis Pigmentosa
NCT01560715	PHASE2	COMPLETED	Autologous Bone Marrow-Derived Stem Cells Transplantation For Retinitis Pigmentosa
NCT02609165	PHASE2	COMPLETED	Nerve Growth Factor Eye Drops Treatment in Patients With Retinitis Pigmentosa and Cystoid Macular Edema
NCT02661711	PHASE2	COMPLETED	Aflibercept for Macular Oedema With Underlying Retinitis Pigmentosa (AMOUR) Study
NCT02804360	PHASE2	UNKNOWN	Intravitreal Dexamethasone Implant in Retinitis Pigmentosa-related Macular Edema- a Retrospective Study
NCT02837640	PHASE2	UNKNOWN	Studying a Potential Protective Effect of L-Dopa on Retinitis Pigmentosa
NCT03073733	PHASE2	COMPLETED	Safety and Efficacy of Intravitreal Injection of Human Retinal Progenitor Cells in Adults With Retinitis Pigmentosa
NCT04068207	PHASE2	COMPLETED	Minocycline Treatment in Retinitis Pigmentosa
NCT04356716	PHASE2	COMPLETED	Sildenafil for Treatment of Choroidal Ischemia
NCT04604899	PHASE2	COMPLETED	Safety of Repeat Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Adult Subjects With Retinitis Pigmentosa
NCT04763369	PHASE2	UNKNOWN	Investigation of Therapeutic Efficacy and Safety of UMSCs for the Management of Retinitis Pigmentosa (RP)
NCT04864496	PHASE2	UNKNOWN	Effects of Treatment With N- Acetylcysteine on Visual Outcomes in Patients With Retinitis Pigmentosa
NCT04945772	PHASE2	COMPLETED	Efficacy and Safety of MCO-010 Optogenetic Therapy in Adults With Retinitis Pigmentosa [RESTORE]
NCT05085964	PHASE2	TERMINATED	An Open-Label Extension Study to Evaluate Safety & Tolerability of QR-421a in Subjects With Retinitis Pigmentosa
NCT05392179	PHASE2	COMPLETED	A Study in Subjects With Retinitis Pigmentosa
NCT06627179	PHASE2	RECRUITING	Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene
NCT06628947	PHASE2	RECRUITING	A Phase II Study of Intravitreal KIO-301 in Patients With Late-stage Retinitis Pigmentosa
NCT06912633	PHASE2	RECRUITING	Safety of a Single, Intravitreal Injection of 6.0M jCell (Famzeretcel) in Retinitis Pigmentosa (RP)
NCT03763227	PHASE2	COMPLETED	Intravitreal Ranibizumab (Lucentis®) in the Treatment of Non-leaking Macular Cysts in Retinal Dystrophy
NCT00063765	PHASE1	COMPLETED	Evaluation of Safety of Ciliary Neurotrophic Factor Implants in the Eye
NCT00065455	PHASE1	COMPLETED	Investigating the Effect of Vitamin A Supplementation on Retinitis Pigmentosa
NCT00458575	PHASE1	TERMINATED	A Study to Evaluate the Safety of CNTO 2476 in Patients With Advanced Retinitis Pigmentosa